<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD"><gtr:id>59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD</gtr:id><gtr:name>The Pirbright Institute</gtr:name><gtr:department>Vector-borne Viral Diseases</gtr:department><gtr:address><gtr:line1>Ash Road</gtr:line1><gtr:line2>Pirbright</gtr:line2><gtr:line4>Woking</gtr:line4><gtr:line5>Surrrey</gtr:line5><gtr:postCode>GU24 0NF</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD"><gtr:id>59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD</gtr:id><gtr:name>The Pirbright Institute</gtr:name><gtr:address><gtr:line1>Ash Road</gtr:line1><gtr:line2>Pirbright</gtr:line2><gtr:line4>Woking</gtr:line4><gtr:line5>Surrrey</gtr:line5><gtr:postCode>GU24 0NF</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/1EA34DDE-41A8-440F-9F97-048DECC21142"><gtr:id>1EA34DDE-41A8-440F-9F97-048DECC21142</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:otherNames>Lewis</gtr:otherNames><gtr:surname>Netherton</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/70FC2983-CD4D-4F05-B6F7-DA5E6BE96736"><gtr:id>70FC2983-CD4D-4F05-B6F7-DA5E6BE96736</gtr:id><gtr:firstName>Linda</gtr:firstName><gtr:surname>Dixon</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/5DC8742C-F283-44E9-9393-25DE98BDE551"><gtr:id>5DC8742C-F283-44E9-9393-25DE98BDE551</gtr:id><gtr:firstName>Geraldine</gtr:firstName><gtr:surname>Taylor</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=BB%2FL004267%2F1"><gtr:id>09A222D3-6D63-4B3E-8F51-EE6FD4F3E1BF</gtr:id><gtr:title>Further development of an African swine fever virus live attenuated vaccine</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/L004267/1</gtr:grantReference><gtr:abstractText>African swine fever virus (ASFV) causes a severe disease of domestic pigs that can result in up to 100% mortality and has severe socio-economic impacts. ASFV is endemic in most sub-Saharan African countries and Sardinia. Since introduction of ASF in 2007 to Georgia, the disease has rapidly spread through the Russian Federation and the risk of further spread has increased. The lack of a vaccine limits options for disease control. Attenuated ASFV strain OURT88/3 induces good levels of protection in pigs against lethal challenge with virulent virus. Commercial development of this strain as a vaccine has been hampered by the lack of a suitable cell line to propagate the virus. We have now identified a pig macrophage cell line can be infected by OURT88/3 strain and the virus grown in these cells can still induce protection in pigs. We will investigate the use of this cell line for ASFV vaccine strain production and diagnosis. We will also identify partners for commercial development</gtr:abstractText><gtr:fund><gtr:end>2017-08-16</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2014-02-17</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>550630</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Expert panel on African swine fever virus whole genome sequencing and bioinformatics</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>EB58C80C-D034-43BE-8E1A-7DE1F68E7700</gtr:id><gtr:impact>Member of expert working group to discuss methods for African swine fever virus complete genome sequencing . Attendance at working group meeting in Nairobi Kenya.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Study participants or study members</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Agritech Forum Kiev Ukraine</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C69B261C-38BC-4F8F-B3FE-4BEA67524C94</gtr:id><gtr:impact>I was invited by the UK Department of Trade and Industry to attend an Agritech Business Forum in Kiev Ukraine. I gave a presentation at a workshiop they organised and met with Ukrainian businesses, Vets, Policy makers and Farmers</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Laboratory Training to Postgraduate MSC students</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>EF21871E-6543-4826-A724-3D79D25027C8</gtr:id><gtr:impact>Training and knowledge exchange to MSC Veterinary Microbiology students from Surrey University</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Communication on Understanding Animal Research</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>1BEA3665-A4BD-4F94-9E16-4FC39C49F17E</gtr:id><gtr:impact>I gave a presentation and discussed with students at Woking College my work and more generally in use of animals in research.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Organising Committee EPIZONE Annual Workshop</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E5BDA596-87B7-49EA-9452-5515D64EA248</gtr:id><gtr:impact>I have been a member of the scientific organizing committee of the EU EPIZONE Network every year since its founding in 2005 except for 2015.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.epizone-eu.net</gtr:url><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visiting Scientist from CReSA Barcelona</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>26912A47-58DC-42CC-B891-FF6C1295216A</gtr:id><gtr:impact>A postgraduate student from CReSA Barcelona visited for collaborative research and training for 6 months</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Representative at Pig and Poultry Fair, Stoneleigh UK</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>16C32A74-9151-48FC-89F4-5A518E584B6D</gtr:id><gtr:impact>I represented The Pirbright Institute at a Stand at the Pig and Poultry Fair, Stoneleigh Warwickshire and discussed with farmers, vets, policy makers, schools</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visit to QIA Institute S Korea</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1153DDC7-DDBA-4EE0-95A5-70FC969C69DC</gtr:id><gtr:impact>Visit to QIA Institute S Korea to provide expert advice on ASFV</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Member of Expert Group on Roadmap and Blueprint for an African swine fever vrius vaccine</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A89AA1B5-8EE7-4E2D-9E93-A07D95DB7600</gtr:id><gtr:impact>I was a member of an EU commissioned working group on preparation of a Roadmap and Blueprint for an African swine fever virus vaccine. The group comprised ~ 15 experts. One 2 day face to face meeting, a telephone conference were held in addition to preparation of a 36 page report. 
The aim of the ASF blueprint and roadmap is to give an overview of the research efforts needed and help to direct investments towards specific areas.

The STRATEGIC GOALS identified include:
?Identification of potential strategies for vaccine development based on existing data/knowledge in a view of an effective and safe vaccine.
?Identification of gaps and needs for vaccine development and manufacturing following the Good Manufacturing Practice Standards.
?Identification of a network of dedicated laboratories directed towards vaccine development
?Identification of the research steps (Roadmap)
The report has been published on the EU website http://ec.europa.eu/food/sites/food/files/safety/docs/cff_animal_vet-progs_asf_blue-print-road-map.pdf</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:url>http://ec.europa.eu/food/sites/food/files/safety/docs/cff_animal_vet-progs_asf_blue-print-road-map.pdf</gtr:url><gtr:year>2016,2017</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>550000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Zoetis Research Funding</gtr:description><gtr:end>2018-10-02</gtr:end><gtr:fundingOrg>Zoetis</gtr:fundingOrg><gtr:id>24E14978-FB16-417F-AE51-5A95EBF6865E</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>216000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>GALVmed DFID Funding</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>GALVmed</gtr:fundingOrg><gtr:id>178C0362-D8CC-4733-9694-C1559C5EC662</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>The results from the award will support the commercial development of a vaccine for African swine fever virus thus helping to protect the UK and global pig industry from this devastating pig disease.</gtr:description><gtr:firstYearOfImpact>2004</gtr:firstYearOfImpact><gtr:id>DFE15F8A-BEF6-4772-882F-BF6C649A2DC2</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:sector>Agriculture, Food and Drink</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>We identified African swine fever virus genes that inhibit the host interferon antiviral response and showed that deletion of these from the virus genome attenuates the virus and can lead to induction of protection against challenge. Thus we identified a route to construct candidate live attenuated vaccines.</gtr:description><gtr:id>E1EFEFDD-FFEF-4D98-8940-36676B08F1D8</gtr:id><gtr:impact>We have initiated a collaboration with Zoetis and GALVmed which has brought new funding to the project.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>Patent PCT/GB2015/051798</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Gene-deleted live attenuated African swine fever vaccine candidate</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>The registration of vaccines requires evaluation of their safety and efficacy at different doses. To evaluate if the naturally attenuated ASFV strain OURT88/3 may meet these requirements we carried out an experiment in which we immunised groups of pigs with different doses (10 e3, 10 e4, 10 e5) and by either intramuscular or intranasal routes. Pigs received a boost immunisation of the same dose and by the same route and were challenged with a virulent isolate in parallel with a group of non-immune pigs. The results showed that the pigs immunised with the two lower doses by the intranasal route were all protected whereas in other groups protection varied between 33% and 66%. Adverse reactions were more severe at the higher dose. The results suggest that the oral/nasal route may be a more effective delivery route. This route may be most useful for delivery of vaccine by bait to wild boar or to piglets.
The protection induced by OURT88/3 was compared with that induced by two ASFV gene deletion mutants. Rational attenuation of virus by deletion of genes would provide a route to construct a vaccine for any of the different genotypes circulating, for example in E. Europe. The results showed these 2 deletion mutants could induce good levels of protection and are promising candidates for further study. 
Discussions have been held with an Industrial partner regarding the possible use of the pig macrophage cell line, obtained from a company in the US, for commercial production of live attenuated ASFV vaccines.</gtr:description><gtr:exploitationPathways>The findings may be taken forward by an Veterinary Vaccine Company for development of the first commercial vaccine for ASFV .</gtr:exploitationPathways><gtr:id>33D56491-C1D4-425B-BBE6-0289EAF37393</gtr:id><gtr:sectors><gtr:sector>Agriculture, Food and Drink</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Science Director Global Alliance for African swine fever virus research</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>54FFDA26-D171-4456-83C4-C92F35D78731</gtr:id><gtr:impact>I was Science Director of the Global Alliance for Research on African swine fever virus (GARA). This involved being Chair of the Scientific Organizing Committee for 2 International Meetings and preparing reports and GAP analysis to direct research.</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>https://www.ars.usda.gov/GARA/</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/36300325-04E2-451C-8D9C-CC1252F180BF"><gtr:id>36300325-04E2-451C-8D9C-CC1252F180BF</gtr:id><gtr:title>Deletion of African swine fever virus interferon inhibitors from the genome of a virulent isolate reduces virulence in domestic pigs and induces a protective response.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e16a44ca574b321d3fbce50cf405e095"><gtr:id>e16a44ca574b321d3fbce50cf405e095</gtr:id><gtr:otherNames>Reis AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4923535E-39AD-4336-BB0F-6C8E6959E924"><gtr:id>4923535E-39AD-4336-BB0F-6C8E6959E924</gtr:id><gtr:title>Different routes and doses influence protection in pigs immunised with the naturally attenuated African swine fever virus isolate OURT88/3.</gtr:title><gtr:parentPublicationTitle>Antiviral research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3c598a0b67d2909cf4e2298949ee52df"><gtr:id>3c598a0b67d2909cf4e2298949ee52df</gtr:id><gtr:otherNames>S?nchez-Cord?n PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0166-3542</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D76B3B78-50FF-4B86-BB40-870417DE77B2"><gtr:id>D76B3B78-50FF-4B86-BB40-870417DE77B2</gtr:id><gtr:title>Encyclopedia of Cell Biology</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a1eb115a44cc87d30218cf02d50091e1"><gtr:id>a1eb115a44cc87d30218cf02d50091e1</gtr:id><gtr:otherNames>Wileman T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:isbn>9780123947963</gtr:isbn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9B594FAD-EE0C-4D50-B885-45C4C5A2A9EF"><gtr:id>9B594FAD-EE0C-4D50-B885-45C4C5A2A9EF</gtr:id><gtr:title>Unraveling the Armor of a Killer: Evasion of Host Defenses by African Swine Fever Virus.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e16a44ca574b321d3fbce50cf405e095"><gtr:id>e16a44ca574b321d3fbce50cf405e095</gtr:id><gtr:otherNames>Reis AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/L004267/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>